Yumanity Therapeutics, Inc. YMTX
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 20.52M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -0.38
- Beta
- 0.00
- Short ratio
- 1.24
- Inst. own
- 22.57%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 14, 2022
- 50-d avg
- 1.77
- 200-d avg
- 1.59
- 1y target
- 35.00
Key statistics
- Market cap
- 20.52M
- Enterprise value
- 135.42M
- Trailing P/E
- 0.00
- Forward P/E
- -0.38
- PEG ratio
- 0.00
- Price / sales
- 4.24
- Price / book
- 3.75
- EPS (TTM)
- -4.24
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 4.84M
- Revenue growth
- -14.30%
- Free cash flow
- -15.02M
- Total cash
- 8.42M
- Total debt
- 204.00K
- Return on equity
- -168.66%
- Shares outstanding
- 10.86M
- Short % of float
- 0.64%
- 50-day average
- 1.77
- 200-day average
- 1.59
Analyst view
Consensus: buy
Next earnings
Nov 14, 2022
Expected Nov 14, 2022. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -1.13 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -1.02 | — | — | — |
| Mar 24, 2022 | Dec 1, 2021 | -1.00 | — | — | — |
| Nov 15, 2021 | Sep 1, 2021 | -1.13 | — | — | — |
| Aug 12, 2021 | Jun 1, 2021 | -0.84 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 4, 2021 | HC Wainwright & Co. | init | — | Buy |
| Apr 1, 2021 | Jefferies | init | — | Buy |
About Yumanity Therapeutics, Inc.
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- yumanity.com
News
- Why Are Chinese Stocks Up Today?
- Why Is Yumanity Therapeutics (YMTX) Stock Up Today?
- Best Penny Stocks to Buy That Exploded Today? 3 to Watch
- Why Is Yumanity Therapeutics (YMTX) Stock Up 50% Today?
- Yumanity Therapeutics Shares Trading Higher Today - Read Here Why
- Yumanity Therapeutics (YMTX) Reports Q1 Loss, Misses Revenue Estimates
- Stocks That Hit 52-Week Lows On Monday
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Tuesday
- 52 Biggest Movers From Yesterday
Your note
Sign in to keep a note on YMTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COLES N. ANTHONY | Officer and Director | Stock Award(Grant) | Jan 31, 2021 | 743,677 |
| EPSTEIN MARIE N. | Officer | Sale | Dec 1, 2022 | 8,883 |
| HEYMAN RICHARD A | Director | Stock Award(Grant) | Jan 31, 2021 | 8,117 |
| KELLY JEFFERY W. | Director | Stock Award(Grant) | Jan 31, 2021 | 13,237 |
| MOHSEN PAULASH | Officer | Sale | Feb 2, 2022 | 59,135 |
| PETERS RICHARD | Chief Executive Officer | Sale | Dec 1, 2022 | 90,028 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 15.00% | 1,628,470 | 3.08M | Sep 29, 2022 |
| Vanguard Group, Inc. (The) | 2.42% | 262,343 | 495.83K | Sep 29, 2022 |
| Artal Group S.A. | 2.00% | 217,391 | 410.87K | Sep 29, 2022 |
| Renaissance Technologies, LLC | 0.63% | 68,722 | 129.88K | Sep 29, 2022 |
| Geode Capital Management, LLC | 0.51% | 55,533 | 104.96K | Sep 29, 2022 |
| Citadel Advisors Llc | 0.46% | 49,543 | 93.64K | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 4.69% | 509,001 | 962.01K | Oct 30, 2022 |
| Fidelity Select Portfolios - Biotechnology | 2.40% | 260,182 | 491.74K | Oct 30, 2022 |
| Vanguard Total Stock Market Index Fund | 2.13% | 230,835 | 436.28K | Sep 29, 2022 |
| Fidelity Growth Company K6 Fund | 1.23% | 133,373 | 252.07K | Oct 30, 2022 |
| Fidelity Series Growth Company Fund | 0.76% | 82,392 | 155.72K | Oct 30, 2022 |
| Vanguard Extended Market Index Fund | 0.27% | 29,192 | 55.17K | Sep 29, 2022 |